var data={"title":"Micafungin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Micafungin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6578?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=micafungin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Micafungin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=micafungin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Micafungin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196257\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mycamine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5505640\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mycamine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196267\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Parenteral;</li>\n      <li>\n        Echinocandin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196258\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, invasive (salvage therapy) (off-label use): </b>IV: 100 to 150 mg once daily. Minimum duration of therapy is 6 to 12 weeks, although duration is highly dependent on degree/duration of immunosuppression, disease site, and evidence of disease improvement (IDSA [Patterson 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidemia, acute disseminated candidiasis, and <i>Candida</i> peritonitis and abscesses:</b> IV: 100 mg once daily; mean duration of therapy (from clinical trials) was 15 days (range: 10 to 47 days).  <b>Note:</b> For treatment of candidemia, IDSA Candidiasis guidelines recommend a total duration of antifungal therapy of at least 2 weeks <i>after</i> the documented clearance of <i>Candida</i> from the bloodstream and resolution of candidemia-associated symptoms in patients without metastatic complications; may transition to fluconazole (eg, after 5 to 7 days in non-neutropenic patients) in clinically stable patients, with fluconazole-susceptible isolates and negative repeat cultures (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, chronic disseminated (hepatosplenic) (off-label use):</b> IV: 100 mg daily for several weeks, followed by oral fluconazole therapy (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, empiric therapy (suspected invasive candidiasis in non-neutropenic ICU patients) (off-label use): </b>IV: 100 mg daily; treatment should continue for 14 days in patients showing clinical improvement. Consider discontinuing after 4 to 5 days in patients with no clinical response (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, intravascular infections (native or prosthetic valve endocarditis, infection of implantable cardiac devices, suppurative thrombophlebitis) (off-label use):</b> IV: 150 mg daily. For native or prosthetic valve endocarditis, therapy should continue for at least 6 weeks after valve replacement surgery (longer durations in patients with abscesses or other complications); for patients with implantable cardiac devices, therapy should continue for 4 to 6 weeks after surgery (4 weeks for infections limited to generator pockets and at least 6 weeks for infections involving the wires); for suppurative thrombophlebitis, after catheter removal, continue for at least 2 weeks after candidemia has cleared.  <b>Note:</b> Step-down to fluconazole therapy is recommended in clinically stable patients and fluconazole-susceptible isolates with negative repeat cultures (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, osteoarticular infections (osteomyelitis or septic arthritis) (alternative therapy) (off-label use):</b> IV: 100 mg daily for at least 14 days, followed by fluconazole therapy (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, oropharyngeal (refractory disease) (alternative therapy) (off-label use): </b>IV: 100 mg once daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Empiric antifungal therapy (neutropenic fever) (off-label use): </b>IV: 100 mg once daily (IDSA [Patterson 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal candidiasis: </b>IV: 150 mg once daily; mean duration of therapy (from clinical trials) was 15 days (range: 10 to 30 days). <b>Note:</b> IDSA Candidiasis guidelines suggest considering a transition to oral fluconazole therapy once oral intake tolerable. In patients with fluconazole-refractory disease, continue micafungin for 14 to 21 days (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of <i>Candida</i> infections: </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>In hematopoietic stem cell transplantation</i>: 50 mg once daily; mean duration of therapy (from clinical trials) was 19 days (range: 6 to 51 days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>In high-risk ICU patients in units with high incidence of invasive candidiasis (alternative therapy; off-label use):</i> 100 mg daily (Pappas [IDSA 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21664241\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=micafungin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Micafungin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidemia, acute disseminated candidiasis, and <i>Candida</i> peritonitis and abscesses:</b> Infants &ge;4 months, Children, and Adolescents: IV: 2 mg/kg once daily; maximum: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal candidiasis:</b> Infants &ge;4 months, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&le;30 kg: 3 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;30 kg: 2.5 mg/kg once daily; maximum: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of <i>Candida</i> infection in hematopoietic stem cell transplantation:</b> Infants &ge;4 months, Children, and Adolescents: IV: 1 mg/kg once daily; maximum: 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary antifungal prophylaxis in allogeneic HSCT (when fluconazole is contraindicated; off-label dosing/population; guideline recommendation):</b> Infants &ge;1 month, Children, and Adolescents &lt;19 years: IV: 1 mg/kg once daily; maximum: 50 mg once daily (Science, 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062601\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5272307\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5272308\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196241\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mycamine: 50 mg (1 ea); 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mycamine: 50 mg (1 ea); 100 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3884043\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196243\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For intravenous use only; infuse over 1 hour. When used in children, administer infusions &gt;1.5 mg/mL via central catheter to minimize risk of infusion reactions. Flush line with NS prior to administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196242\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidemia, acute disseminated candidiasis, <i>Candida</i> peritonitis and abscesses:</b> Treatment of candidemia, acute disseminated candidiasis, <i>Candida</i> peritonitis and abscesses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal candidiasis:</b> Treatment of esophageal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of <i>Candida</i> infections:</b> Prophylaxis of <i>Candida</i> infections in patients undergoing hematopoietic stem cell transplantation (HSCT)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25732718\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Aspergillosis, invasive (salvage therapy); Candidiasis, intravascular infections; Candidiasis, osteoarticular infections; Candidiasis, chronic disseminated (hepatosplenic); Candidiasis empiric therapy (non-neutropenic ICU patients); Candidiasis, oropharyngeal (refractory disease); Candidiasis, prophylaxis against invasive candidiasis (high-risk ICU patients); Empiric antifungal therapy (neutropenic fever); Primary antifungal prophylaxis in oncology patients (children/adolescents)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196235\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Phlebitis (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Vomiting (7% to 18%), diarrhea (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Anemia (pediatric: 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Abnormal hepatic function tests (pediatric: &lt;15%), hyperbilirubinemia (pediatric: &lt;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Renal: Abnormal hepatic function tests (4%; pediatrics: &lt;15%), renal failure (&lt;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Atrial fibrillation (adults: 3% to 5%), tachycardia (pediatric: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Headache (adults: 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Skin rash (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hypoglycemia (adults: 6% to 7%), hypernatremia (adults: 4% to 6%), hyperkalemia (adults: 4% to 5%), abnormal aspartate transaminase (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Nausea (7% to 10%), abdominal pain (pediatric: 4%), abdominal distention (pediatric: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Thrombocytopenia (pediatric: 9%), neutropenia (pediatric: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Increased serum alkaline phosphatase (3% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Candidiasis prophylaxis in hematopoietic stem cell transplantation</b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Tachycardia (16% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Headache (adults: 44%), insomnia (adults: 37%), anxiety (22% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Pruritus (pediatric: 33%), skin rash (25% to 30%), urticaria (&lt;5%; pediatric: 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Abnormal alanine aminotransferase (pediatric: 16%, increased)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Diarrhea (77%; pediatric: 51%), nausea (70% to 71%), vomiting (65% to 66%), diarrhea (pediatric: 51%), abdominal pain (26% to 35%), abdominal distention (pediatric: 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Decreased urine output (pediatric: 23%), hematuria (pediatric: 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Neutropenia (75% to 77%), thrombocytopenia (72% to 75%), anemia (pediatric: 51%), febrile neutropenia (pediatric: 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Abnormal hepatic function tests (pediatric: &lt;15%), hyperbilirubinemia (pediatric: &lt;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Renal: Renal failure (pediatric: &lt;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever (pediatric: 61%), infusion-related reaction (pediatric: 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Cardiac arrest (&lt;5%), myocardial infarction (&lt;5%), pericardial effusion (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Brain disease (&lt;5%), delirium (&lt;5%), intracranial hemorrhage (&lt;5%), seizure (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Blood coagulation disorder (&lt;5%), pancytopenia (&lt;5%), thrombotic thrombocytopenic purpura (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hepatic: Hepatic failure (&lt;5%), hepatic injury (&lt;5%), hepatomegaly (&lt;5%), jaundice (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypersensitivity: Anaphylaxis (&lt;5%), hypersensitivity reaction (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local: Infusion site reaction (&lt;5%), venous thrombosis at injection site (&lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Epistaxis (pediatric: 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports (all indications): Disseminated intravascular coagulation, hepatic disease, renal insufficiency, shock, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196246\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to micafungin, other echinocandins, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196233\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemolytic anemia/hemoglobinuria: Hemolytic anemia and hemoglobinuria have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: New-onset or worsening hepatic impairment, including hepatitis and hepatic failure, has been reported. Monitor closely and evaluate appropriateness of continued use in patients who develop abnormal liver function tests during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Severe anaphylactic reactions, including shock, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Increased BUN, serum creatinine, renal dysfunction, and/or acute renal failure has been reported; use with caution in patients that develop worsening renal function during treatment; monitor closely. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F747105\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F747104\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10141&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: Micafungin may increase the serum concentration of Sirolimus. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196238\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196248\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616328\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if micafungin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering micafungin to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196239\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196232\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Concentration-dependent inhibition of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, an essential polysaccharide comprising 30% to 60% of <i>Candida</i> cell walls (absent in mammalian cells); decreased glucan content leads to osmotic instability and cellular lysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196245\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Poor </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes into lung, liver, and spleen; minimally to CNS and eyes (Caudle 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm infants (ELBW): Reported data highly variable; possibly dependent on GA/weight, and PNA: V<sub>dss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 0-1 day: 0.76 L/kg (Kawada 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 4 days: 1.52 L/kg (Smith 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &gt;3 weeks: 0.43 L/kg (range: 0.28 to 0.66 L/kg) (Heresi 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to 8 years: V<sub>dss</sub>: 0.35 &plusmn; 0.18 L/kg (Seibel 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 9 to 17 years: V<sub>dss</sub>: 0.28 &plusmn; 0.09 L/kg (Seibel 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: V<sub>d</sub>: 0.39 &plusmn; 0.11 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Neonates: 96.7% (Yanni 2011); Adults: &gt;99% to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to M-1, catechol form by arylsulfatase; further metabolized to M-2, methoxy form by catechol-O-methyltransferase; hydroxylation to M-5 by CYP3A </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm infants: PNA &lt;1 week: 6.7 hours (Kawada 2009); PNA &gt;3 weeks: Mean 8.3 hours (range: 5.6 to 11 hours) (Heresi 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 months to 16 years: &le;30 kg: 12.5 &plusmn; 4.6 hours; &gt;30 kg: 13.6 &plusmn; 8.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Healthy Adults: 11 to 21 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults receiving bone marrow or peripheral stem-cell transplantation: 10.7 to 13.5 hours (Carver 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily feces (71%); urine (&lt;1%, unchanged [Herbert 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm infants: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 0 to 1 day: 1.48 mL/minute/kg (Kawada 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 4 days: 0.58 mL/minute (Smith 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &gt;3 weeks: 0.64 mL/minute (Heresi 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 months to 16 years: &le;30 kg: 0.328 mL/minute/kg; &gt;30 kg: 0.241 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~0.3 mL/minute/kg </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323399\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Mycamine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $112.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $224.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038681\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Funguard (JP);</li>\n      <li>Micamin (RU);</li>\n      <li>Mikamin (UA);</li>\n      <li>Mycamiine (SK);</li>\n      <li>Mycamine (AT, AU, BB, BR, CH, CN, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HN, HR, ID, IE, IL, IN, IS, IT, JO, KR, KW, LB, LT, LV, MT, MY, NL, NO, PH, PL, PT, QA, RO, SA, SE, SG, SI, TH, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Carver PL, &ldquo;Micafungin,&rdquo; <i>Ann Pharmacother</i>, 2004, 38(10):1707-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/15340133/pubmed\" target=\"_blank\" id=\"15340133\">15340133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caudle KE, Inger AG, Butler DR, et.al. Echinocandin use in the neonatal intensive care unit. <i>Ann Pharmacother</i>. 2012;46:108-116.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/22190252/pubmed\" target=\"_blank\" id=\"22190252\">22190252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Wet N, Llanos-Cuentas A, Suleiman J, et al, &ldquo;A Randomized, Double-Blind, Parallel-Group, Dose-Response Study of Micafungin Compared With Fluconazole for the Treatment of Esophageal Candidiasis in HIV-Positive Patients,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(6):842-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/15472817/pubmed\" target=\"_blank\" id=\"15472817\">15472817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herbert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. <i>J Clin Pharmacol</i>. 2005;45(10):1145-1152.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/16172179/pubmed\" target=\"_blank\" id=\"16172179\">16172179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heresi GP, Gerstmann DR, Reed MD, et al, &quot;The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants,&quot; <i>Pediatr Infect Dis J</i>, 2006, 25(12):1110-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/17133155/pubmed\" target=\"_blank\" id=\"17133155\">17133155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kawada M, Fukuoka N, Kondo M, et al, &quot;Pharmacokinetics of Prophylactic Micafungin in Very-Low-Birth-Weight Infants,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(9):840-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/19636279/pubmed\" target=\"_blank\" id=\"19636279\">19636279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kohno S, Masaoka T, Yamaguchi H, et al, &ldquo;A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-Seated Mycosis in Japan,&rdquo; <i>Scand J Infect Dis</i>, 36(5):372-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mycamine (micafungin) [prescribing information]. Deerfield, IL: Astellas Pharma Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span><span class=\"doi\">10.1093/cid/civ933</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html. Accessed August 8, 2016.27365388</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pettengell K, Mynhardt J, Kluyts T, et al, &ldquo;Successful Treatment of Oesophageal Candidiasis by Micafungin: A Novel Systemic Antifungal Agent,&rdquo; <i>Aliment Pharmacol Ther</i>, 2004, 20(4):475-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/15298643/pubmed\" target=\"_blank\" id=\"15298643\">15298643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. <i>Pediatr Blood Cancer</i>. 2014;61(3):393-400. doi: 10.1002/pbc.24847.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/24424789/pubmed\" target=\"_blank\" id=\"24424789\">24424789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seibel NL, Schwartz C, Arrieta A, et al, &quot;Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(8):3317-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/16048942/pubmed\" target=\"_blank\" id=\"16048942\">16048942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith PB, Walsh TJ, Hope W, et al, &quot;Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(5):412-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/19319022/pubmed\" target=\"_blank\" id=\"19319022\">19319022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yanni, SB, Smith PB, Benjamin DK, et.al. Higher clearance of micafungin in neonates compared to adults: rose of age-dependent micafungin serum binding. <i>Biopharm Drug Dispos</i>. 2011;32(4):222-232.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/21449041/pubmed\" target=\"_blank\" id=\"21449041\">21449041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yokote T, Akioka T, Oka S, et al, &ldquo;Successful Treatment With Micafungin of Invasive Pulmonary Aspergillosis in Acute Myeloid Leukemia, With Renal Failure Due to Amphotericin B Therapy,&rdquo; <i>Ann Hematol</i>, 2004, 83(1):64-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-drug-information/abstract-text/14661114/pubmed\" target=\"_blank\" id=\"14661114\">14661114</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10141 Version 121.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F196257\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5505640\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F196267\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F196258\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F21664241\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062601\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F5272307\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5272308\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196241\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3884043\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F196243\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F196242\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25732718\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196235\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196246\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196233\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F747105\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F747104\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F196238\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F196248\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20616328\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F196239\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196232\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F196245\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323399\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038681\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10141|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=micafungin-patient-drug-information\" class=\"drug drug_patient\">Micafungin: Patient drug information</a></li><li><a href=\"topic.htm?path=micafungin-pediatric-drug-information\" class=\"drug drug_pediatric\">Micafungin: Pediatric drug information</a></li></ul></div></div>","javascript":null}